Long-term effects of rasagiline and the natural history of treated Parkinson's disease.
Identifieur interne : 001A81 ( Ncbi/Merge ); précédent : 001A80; suivant : 001A82Long-term effects of rasagiline and the natural history of treated Parkinson's disease.
Auteurs : Olivier Rascol [France] ; Robert A. Hauser [États-Unis] ; Fabrizio Stocchi [Italie] ; Cheryl J. Fitzer-Attas [États-Unis] ; Yulia Sidi [Israël] ; Victor Abler [États-Unis] ; C Warren Olanow [États-Unis]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2016.
Abstract
The Attenuation of Disease progression with Azilect GIven Once-daily (ADAGIO) delayed-start study demonstrated a benefit of early-start treatment with rasagiline 1 mg/day versus delayed-start treatment in PD. This follow-up study aimed to assess whether these benefits persist and the clinical progression rate during long-term naturalistic treatment.
DOI: 10.1002/mds.26724
PubMed: 27431201
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000078
- to stream PubMed, to step Curation: 000078
- to stream PubMed, to step Checkpoint: 000078
Links to Exploration step
pubmed:27431201Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term effects of rasagiline and the natural history of treated Parkinson's disease.</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="3"><nlm:affiliation>Departments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC-1436, NS-Park/FCRIN Network and NeuroToul COEN Center of Excellence in Neurodegeneration, INSERM, University Hospital of Toulouse, and University of Toulouse 3, Toulouse, France. olivier.rascol@univ-tlse3.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC-1436, NS-Park/FCRIN Network and NeuroToul COEN Center of Excellence in Neurodegeneration, INSERM, University Hospital of Toulouse, and University of Toulouse 3, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A" last="Hauser">Robert A. Hauser</name><affiliation wicri:level="2"><nlm:affiliation>Parkinson's Disease and Movement Disorders Center, NPF Center of Excellence, Tampa, Florida, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center, NPF Center of Excellence, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name><affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, Institute for Research and Medical Care IRCCS San Raffaele, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurology, Institute for Research and Medical Care IRCCS San Raffaele, Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Fitzer Attas, Cheryl J" sort="Fitzer Attas, Cheryl J" uniqKey="Fitzer Attas C" first="Cheryl J" last="Fitzer-Attas">Cheryl J. Fitzer-Attas</name><affiliation wicri:level="2"><nlm:affiliation>CHDI Management/CHDI Foundation, Princeton, New Jersey, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>CHDI Management/CHDI Foundation, Princeton, New Jersey</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Sidi, Yulia" sort="Sidi, Yulia" uniqKey="Sidi Y" first="Yulia" last="Sidi">Yulia Sidi</name><affiliation wicri:level="1"><nlm:affiliation>Teva Pharmaceuticals, Petah Tikva, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Teva Pharmaceuticals, Petah Tikva</wicri:regionArea><wicri:noRegion>Petah Tikva</wicri:noRegion></affiliation></author><author><name sortKey="Abler, Victor" sort="Abler, Victor" uniqKey="Abler V" first="Victor" last="Abler">Victor Abler</name><affiliation wicri:level="2"><nlm:affiliation>Teva Pharmaceuticals, Frazer, Pennsylvania, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Teva Pharmaceuticals, Frazer, Pennsylvania</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name><affiliation wicri:level="2"><nlm:affiliation>Departments of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27431201</idno><idno type="pmid">27431201</idno><idno type="doi">10.1002/mds.26724</idno><idno type="wicri:Area/PubMed/Corpus">000078</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000078</idno><idno type="wicri:Area/PubMed/Curation">000078</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000078</idno><idno type="wicri:Area/PubMed/Checkpoint">000078</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000078</idno><idno type="wicri:Area/Ncbi/Merge">001A81</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Long-term effects of rasagiline and the natural history of treated Parkinson's disease.</title><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="3"><nlm:affiliation>Departments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC-1436, NS-Park/FCRIN Network and NeuroToul COEN Center of Excellence in Neurodegeneration, INSERM, University Hospital of Toulouse, and University of Toulouse 3, Toulouse, France. olivier.rascol@univ-tlse3.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Departments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC-1436, NS-Park/FCRIN Network and NeuroToul COEN Center of Excellence in Neurodegeneration, INSERM, University Hospital of Toulouse, and University of Toulouse 3, Toulouse</wicri:regionArea><placeName><region type="region">Occitanie (région administrative)</region><region type="old region">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A" last="Hauser">Robert A. Hauser</name><affiliation wicri:level="2"><nlm:affiliation>Parkinson's Disease and Movement Disorders Center, NPF Center of Excellence, Tampa, Florida, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center, NPF Center of Excellence, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name><affiliation wicri:level="3"><nlm:affiliation>Department of Neurology, Institute for Research and Medical Care IRCCS San Raffaele, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurology, Institute for Research and Medical Care IRCCS San Raffaele, Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Fitzer Attas, Cheryl J" sort="Fitzer Attas, Cheryl J" uniqKey="Fitzer Attas C" first="Cheryl J" last="Fitzer-Attas">Cheryl J. Fitzer-Attas</name><affiliation wicri:level="2"><nlm:affiliation>CHDI Management/CHDI Foundation, Princeton, New Jersey, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>CHDI Management/CHDI Foundation, Princeton, New Jersey</wicri:regionArea><placeName><region type="state">New Jersey</region></placeName></affiliation></author><author><name sortKey="Sidi, Yulia" sort="Sidi, Yulia" uniqKey="Sidi Y" first="Yulia" last="Sidi">Yulia Sidi</name><affiliation wicri:level="1"><nlm:affiliation>Teva Pharmaceuticals, Petah Tikva, Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>Teva Pharmaceuticals, Petah Tikva</wicri:regionArea><wicri:noRegion>Petah Tikva</wicri:noRegion></affiliation></author><author><name sortKey="Abler, Victor" sort="Abler, Victor" uniqKey="Abler V" first="Victor" last="Abler">Victor Abler</name><affiliation wicri:level="2"><nlm:affiliation>Teva Pharmaceuticals, Frazer, Pennsylvania, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Teva Pharmaceuticals, Frazer, Pennsylvania</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name><affiliation wicri:level="2"><nlm:affiliation>Departments of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The Attenuation of Disease progression with Azilect GIven Once-daily (ADAGIO) delayed-start study demonstrated a benefit of early-start treatment with rasagiline 1 mg/day versus delayed-start treatment in PD. This follow-up study aimed to assess whether these benefits persist and the clinical progression rate during long-term naturalistic treatment.</div></front></TEI><pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">27431201</PMID><DateCreated><Year>2016</Year><Month>07</Month><Day>19</Day></DateCreated><DateRevised><Year>2016</Year><Month>10</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>10</Issue><PubDate><Year>2016</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Long-term effects of rasagiline and the natural history of treated Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>1489-1496</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.26724</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The Attenuation of Disease progression with Azilect GIven Once-daily (ADAGIO) delayed-start study demonstrated a benefit of early-start treatment with rasagiline 1 mg/day versus delayed-start treatment in PD. This follow-up study aimed to assess whether these benefits persist and the clinical progression rate during long-term naturalistic treatment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The ADAGIO Follow-Up study was initiated approximately 26 months after completion of the ADAGIO study. Patients were followed for 3 years and were treated in an open-label manner with rasagiline 1 mg/day and any other PD treatment that was deemed appropriate. Changes from follow-up baseline to study end in UPDRS scores, and the emergence of clinical milestones (including unsteady gait and/or balance impairment, falls, freezing of gait, and cognitive decline) were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study enrolled 683 patients (58% of the full ADAGIO cohort and 72% of ADAGIO completers). At baseline, mean time from diagnosis was 46.9 months and UPDRS total score was 25.6 units. There were no significant differences in UPDRS total or subscale scores or time to any milestone between patients who were in the original ADAGIO early-start group versus those in the delayed-start group. At study end, patients (total cohort) had worsened by a mean ± standard deviation of 6.0 ± 11.6 UPDRS total units, 3.3 ± 8.6 UPDRS motor units and 2.0 ± 4.0 UPDRS activities of daily living (ADL) units. Overall, 43.6% of patients had onset of unsteady gait/balance impairment, 35.7% had fallen, 26.2% had freezing of gait, and 33.1% had cognitive decline.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The ADAGIO Follow-Up study failed to demonstrate long-term benefits of early-start rasagiline treatment in the prior ADAGIO study. Clinically important milestones occurred in a substantial proportion of patients. © 2016 International Parkinson and Movement Disorder Society.</AbstractText><CopyrightInformation>© 2016 International Parkinson and Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Departments of Clinical Pharmacology and Neurosciences, Clinical Investigation Center CIC-1436, NS-Park/FCRIN Network and NeuroToul COEN Center of Excellence in Neurodegeneration, INSERM, University Hospital of Toulouse, and University of Toulouse 3, Toulouse, France. olivier.rascol@univ-tlse3.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hauser</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Parkinson's Disease and Movement Disorders Center, NPF Center of Excellence, Tampa, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stocchi</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Institute for Research and Medical Care IRCCS San Raffaele, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fitzer-Attas</LastName><ForeName>Cheryl J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>CHDI Management/CHDI Foundation, Princeton, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sidi</LastName><ForeName>Yulia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Teva Pharmaceuticals, Petah Tikva, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abler</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Teva Pharmaceuticals, Frazer, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olanow</LastName><ForeName>C Warren</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>AFU Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">Rasagiline</Keyword><Keyword MajorTopicYN="N">disease progression</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>01</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>06</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>06</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27431201</ArticleId><ArticleId IdType="doi">10.1002/mds.26724</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li><li>Israël</li><li>Italie</li><li>États-Unis</li></country><region><li>Floride</li><li>Latium</li><li>Midi-Pyrénées</li><li>New Jersey</li><li>Occitanie (région administrative)</li><li>Pennsylvanie</li><li>État de New York</li></region><settlement><li>Rome</li><li>Toulouse</li></settlement></list><tree><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></region></country><country name="États-Unis"><region name="Floride"><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A" last="Hauser">Robert A. Hauser</name></region><name sortKey="Abler, Victor" sort="Abler, Victor" uniqKey="Abler V" first="Victor" last="Abler">Victor Abler</name><name sortKey="Fitzer Attas, Cheryl J" sort="Fitzer Attas, Cheryl J" uniqKey="Fitzer Attas C" first="Cheryl J" last="Fitzer-Attas">Cheryl J. Fitzer-Attas</name><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C Warren" last="Olanow">C Warren Olanow</name></country><country name="Italie"><region name="Latium"><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name></region></country><country name="Israël"><noRegion><name sortKey="Sidi, Yulia" sort="Sidi, Yulia" uniqKey="Sidi Y" first="Yulia" last="Sidi">Yulia Sidi</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A81 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001A81 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:27431201
|texte= Long-term effects of rasagiline and the natural history of treated Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:27431201" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |